Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan

References

• World Health Organization. Global tuberculosis control: WHO report 2010. WHO/HTM/TB/2010.7. Geneva: WHO; 2010.
   Google Scholar
• World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. WHO/HTM/TB/2008.393. Geneva: WHO; 2008.
   Google Scholar
• Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis—current problems. J Antimicrob Chemother 1992;29:477–93.
   PubMed Web of Science ®Google Scholar
• Loos U, Musch E, Jense JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985;63:1205–11.
   PubMedGoogle Scholar
• Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998;10:354–9.
   PubMed Web of Science ®Google Scholar
• Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, . Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294–303.
   PubMed Web of Science ®Google Scholar
• Cavenaghi R. Rifampicin raw material characteristics and their effect of bioavailability. Bull Int Union Tuberc Lung Dis 1989;64:36–7.
   PubMedGoogle Scholar
• Seigler DI, Bryant M, Burley DM, Citron M, Standen SM. Effect of meals on rifampicin absorption. Lancet 1974; 2:197–8.
   PubMed Web of Science ®Google Scholar
• Boman G, Lundgren P, Stjernström G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin. Adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 1975;8:293–9.
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18^th WMA General Assembly (1964) Helsinki, Finland and amended by the 59^th WMA General Assembly 2008, Seoul. WMA; 2008.
   Google Scholar
• Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61:544–53.
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Sood A, Sharda N, Kau K, Kaul CL. Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. J Pharm Biomed Anal 1999;18:1013–20.
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79–87.
   PubMed Web of Science ®Google Scholar
• Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV infected tuberculosis patients. Chest 1998;113: 1178–83.
   PubMed Web of Science ®Google Scholar
• Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520–4.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, . Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461–9.
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, . Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008;52:2138–48.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50: 99–110.
   PubMed Web of Science ®Google Scholar
• van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, . Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002;6:497–502.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170–7.
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 2004;271:1–4.
   PubMed Web of Science ®Google Scholar
• Sankar R, Sharda N, Singh S. Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1–3. Drug Dev Ind Pharm 2003;29:733–8.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, . Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781–8.
   PubMed Web of Science ®Google Scholar
• Verbist L. Rifampicin activity ‘in vitro’ and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 1969;60: 397–412.
   PubMedGoogle Scholar
• Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh B N, Jayashree R, . Pharmacokinetics–pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118–24.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1320–30.
   PubMed Web of Science ®Google Scholar
• Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampicin–isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879–94.
   PubMed Web of Science ®Google Scholar
• Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, . The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128–35.
   PubMed Web of Science ®Google Scholar
• Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939–49.
   PubMed Web of Science ®Google Scholar
• Goutelle S, Bourguignon L, Maire PH, Guilder MV, Conte JE Jr, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009;53:2974–81.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, . The early bactericidal activity of high-dose rifampin in patients with sputum smear positive pulmonary tuberculosis. Antimicrob Agents Chemother 2007;51:2994–6.
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5:S440–6.
   PubMedGoogle Scholar
• Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11:699–707.
   PubMed Web of Science ®Google Scholar